-
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | 8.2 |
|---|---|
| Target Price | 30.714 |
| Beta | 1.34 |
| Market Cap | 113M |
| Dividend Yield | None |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HVO.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025